Cargando…

HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies

HOXC cluster antisense RNA 3 (HOXC-AS3) is a novel long noncoding RNA (lncRNA) that exhibits aberrant expression patterns in various cancer types. Its expression is closely related to clinicopathological features, demonstrating significant clinical relevance across multiple tumors. And HOXC-AS3 play...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yunhe, Ye, Jiarong, Luo, Hongliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612484/
https://www.ncbi.nlm.nih.gov/pubmed/37899986
http://dx.doi.org/10.2147/OTT.S425523
_version_ 1785128711320764416
author Xie, Yunhe
Ye, Jiarong
Luo, Hongliang
author_facet Xie, Yunhe
Ye, Jiarong
Luo, Hongliang
author_sort Xie, Yunhe
collection PubMed
description HOXC cluster antisense RNA 3 (HOXC-AS3) is a novel long noncoding RNA (lncRNA) that exhibits aberrant expression patterns in various cancer types. Its expression is closely related to clinicopathological features, demonstrating significant clinical relevance across multiple tumors. And HOXC-AS3 plays multifaceted roles in tumor progression, impacting cell proliferation, apoptosis, migration, invasion, epithelial-mesenchymal transition (EMT), autophagy, senescence, tumor growth, and metastasis. In this review, we summarized and comprehensively analyzed the expression and clinical significance of HOXC-AS3 as a diagnostic and prognostic biomarker for malignancies. Additionally, we presented an in-depth update on HOXC-AS3’s functions and regulatory mechanisms in cancer pathogenesis. This narrative review underscores the importance of HOXC-AS3 as a promising lncRNA candidate in cancer research and its potential as a predictive biomarker and therapeutic target in clinical applications.
format Online
Article
Text
id pubmed-10612484
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-106124842023-10-29 HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies Xie, Yunhe Ye, Jiarong Luo, Hongliang Onco Targets Ther Review HOXC cluster antisense RNA 3 (HOXC-AS3) is a novel long noncoding RNA (lncRNA) that exhibits aberrant expression patterns in various cancer types. Its expression is closely related to clinicopathological features, demonstrating significant clinical relevance across multiple tumors. And HOXC-AS3 plays multifaceted roles in tumor progression, impacting cell proliferation, apoptosis, migration, invasion, epithelial-mesenchymal transition (EMT), autophagy, senescence, tumor growth, and metastasis. In this review, we summarized and comprehensively analyzed the expression and clinical significance of HOXC-AS3 as a diagnostic and prognostic biomarker for malignancies. Additionally, we presented an in-depth update on HOXC-AS3’s functions and regulatory mechanisms in cancer pathogenesis. This narrative review underscores the importance of HOXC-AS3 as a promising lncRNA candidate in cancer research and its potential as a predictive biomarker and therapeutic target in clinical applications. Dove 2023-10-24 /pmc/articles/PMC10612484/ /pubmed/37899986 http://dx.doi.org/10.2147/OTT.S425523 Text en © 2023 Xie et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Xie, Yunhe
Ye, Jiarong
Luo, Hongliang
HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies
title HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies
title_full HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies
title_fullStr HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies
title_full_unstemmed HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies
title_short HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies
title_sort hoxc cluster antisense rna 3, a novel long non-coding rna as an oncological biomarker and therapeutic target in human malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612484/
https://www.ncbi.nlm.nih.gov/pubmed/37899986
http://dx.doi.org/10.2147/OTT.S425523
work_keys_str_mv AT xieyunhe hoxcclusterantisenserna3anovellongnoncodingrnaasanoncologicalbiomarkerandtherapeutictargetinhumanmalignancies
AT yejiarong hoxcclusterantisenserna3anovellongnoncodingrnaasanoncologicalbiomarkerandtherapeutictargetinhumanmalignancies
AT luohongliang hoxcclusterantisenserna3anovellongnoncodingrnaasanoncologicalbiomarkerandtherapeutictargetinhumanmalignancies